REFERENCES
- Shrigui C: treatment of clozapine-induced enuresis with des-mopressin. San Francisco: American Psychiatric Association Annual Meeting, May 1993
- Janssen P, Niemegeers C, Awouters F, Schellekens K, Megens A, and Meert T: Pharmacology of risperidone (R64766), a new an tipsychotic with serotonin-S2 and dopamine D2 an-tagonistic properties. J Pharmacol Exp Ther 1988; 244:685–693
- Meltzer H: Clinical studies of the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophre-nia. Psychopharmacology 1989; 99:S18—S27
- Meco G, Bedini L, Bonifati V, Sonsini U: Risperidone in the treatment of schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo. Curr Ther Res 1989; 46:876–883
- Lieberman J, Saltz B, Johns C, Pollack J, Borenstein M, Kane J: The effects of clozapine on tardive dyskinesia. Br J Psy-chiatry 1991; 158:503–510
- Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment resistant schizophrenic. Arch Gen Psychiatry 1988; 45:789–796
- Castelao F, Ferreira L, Gelders YG, Heylen SLE: Risperi-done (R64766) in the treatment of therapy-resistant chronic psychotic patients: An open dose-finding study. Schizo Res 1989; 2:411–415
- Chouinard G, Arnott W: Clinical review of risperidone. Can J Psychiatry 1993; 38:S89—S95
- Brier A, Buchanan R, Kirkpatrick B, Davis 0, Irish D, Sum-merfelt A, Carpenter W: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20–26
- Fitton A, Heel R: Clozapine, a review of its pharmacologic properties and therapeutic use in schizophrenia. Drugs 1990; 40:722–747
- Ereshefsky L, Lacombe S: Pharmacological profile of risperi-done. Can J Psychiatry 1993; 38:S80—S88
- McEvoy GK: AHFS, Drug Information 93. American Hospi-tal Formulary Service, 1993